Enhanced Permeability and Retention effect: Difference between revisions
No edit summary |
m Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
The '''Enhanced Permeability and Retention''' ('''EPR''') '''effect''' is the property by which certain sizes of molecules, typically [[liposomes]] or macromolecular drugs, tend to accumulate in tumor tissue much more than they do in normal tissues<sup>1,2,3</sup>. The general explanation that is given for this phenomenon is that, in order for tumor cells to grow quickly, they must stimulate the production of blood vessels (VEGF).Tumor cell aggregates of size as small as 150-200 um, start to become dependent on blood supply carried out by neovasculature for their nutritional and oxygen supply . This newly formed tumor vessels are usually abnormal in form and architecture. They are poorly aligned defective endothelial cells with wide fenestration, lacking smooth muscle layer, or inervation with wider lumen, and impaired functional receptors for angiotensin II. Furthermore, tumor tissues usually lack effective lymphatic drainage . All these factors will lead to abnormal molecular and fluid transport dynamics especially for macromolecular drugs. Namely, this phenomenon was coined “enhanced permeability and retention (EPR)-effect” of macromolecules and lipids in solid tumors . The EPR-effect is even more enhanced by great many pathophysiological factors involved in enhancement of extravasation of macromolecules in solid tumor tissues. For instance, bradykinin, nitric oxide / peroxynitrite, prostaglandins, vascular permeability factor (also known as vascular endothelial growth factor VEGF), tumor necrosis factor and others . | The '''Enhanced Permeability and Retention''' ('''EPR''') '''effect''' is the property by which certain sizes of molecules, typically [[liposomes]] or macromolecular drugs, tend to accumulate in tumor tissue much more than they do in normal tissues<sup>1,2,3</sup>. The general explanation that is given for this phenomenon is that, in order for tumor cells to grow quickly, they must stimulate the production of blood vessels (VEGF).Tumor cell aggregates of size as small as 150-200 um, start to become dependent on blood supply carried out by neovasculature for their nutritional and oxygen supply . This newly formed tumor vessels are usually abnormal in form and architecture. They are poorly aligned defective endothelial cells with wide fenestration, lacking smooth muscle layer, or inervation with wider lumen, and impaired functional receptors for angiotensin II. Furthermore, tumor tissues usually lack effective lymphatic drainage . All these factors will lead to abnormal molecular and fluid transport dynamics especially for macromolecular drugs. Namely, this phenomenon was coined “enhanced permeability and retention (EPR)-effect” of macromolecules and lipids in solid tumors . The EPR-effect is even more enhanced by great many pathophysiological factors involved in enhancement of extravasation of macromolecules in solid tumor tissues. For instance, bradykinin, nitric oxide / peroxynitrite, prostaglandins, vascular permeability factor (also known as vascular endothelial growth factor VEGF), tumor necrosis factor and others . | ||
| Line 10: | Line 10: | ||
3. Vasey P. A., Kaye S. B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A. H., Murray L. S., Hilditch T. E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res., 5: 83-94, 1999 | 3. Vasey P. A., Kaye S. B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A. H., Murray L. S., Hilditch T. E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res., 5: 83-94, 1999 | ||
[[Category: | [[Category: Tissues]] | ||
[[Category; Molecules]] | |||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 02:15, 9 August 2012
The Enhanced Permeability and Retention (EPR) effect is the property by which certain sizes of molecules, typically liposomes or macromolecular drugs, tend to accumulate in tumor tissue much more than they do in normal tissues1,2,3. The general explanation that is given for this phenomenon is that, in order for tumor cells to grow quickly, they must stimulate the production of blood vessels (VEGF).Tumor cell aggregates of size as small as 150-200 um, start to become dependent on blood supply carried out by neovasculature for their nutritional and oxygen supply . This newly formed tumor vessels are usually abnormal in form and architecture. They are poorly aligned defective endothelial cells with wide fenestration, lacking smooth muscle layer, or inervation with wider lumen, and impaired functional receptors for angiotensin II. Furthermore, tumor tissues usually lack effective lymphatic drainage . All these factors will lead to abnormal molecular and fluid transport dynamics especially for macromolecular drugs. Namely, this phenomenon was coined “enhanced permeability and retention (EPR)-effect” of macromolecules and lipids in solid tumors . The EPR-effect is even more enhanced by great many pathophysiological factors involved in enhancement of extravasation of macromolecules in solid tumor tissues. For instance, bradykinin, nitric oxide / peroxynitrite, prostaglandins, vascular permeability factor (also known as vascular endothelial growth factor VEGF), tumor necrosis factor and others .
1. Matsamura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanisms of tumoritropic accumulation of protein and the antitumor agent SMANCS. Cancer Res., 46: 6387-6392, 1986.
2. Duncan R., Sat Y-N. Tumour targeting by enhanced permeability and retention (EPR) effect. Ann. Oncol., 9 (Suppl.2): 39 1998
3. Vasey P. A., Kaye S. B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A. H., Murray L. S., Hilditch T. E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res., 5: 83-94, 1999 Category; Molecules